Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06360042
Status:
RECRUITING
Last Update Posted:
2024-04-22
First Post:
2024-02-27
Brief Title:
Anti-PD-1PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Organization Data
Organization:
Peking University Cancer Hospital Institute
Class:
OTHER
Study ID:
MA-HCC-II-021
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Peking University Cancer Hospital Institute
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None